Related Experiment Videos
Visual outcome in surgically treated suprasellar meningiomas
Carlos Filipe Chicani1, Neil R Miller
1Neuro-Ophthalmology Unit, Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD USA.
Summary
Long-term outcomes for suprasellar meningioma surgery show excellent visual prognosis, but tumor recurrence is common, even after complete resection. Regular monitoring is crucial for early detection and treatment of recurrences.
Area of Science:
- Neurosurgery
- Ophthalmology
- Oncology
Background:
- Suprasellar meningiomas are tumors located above the optic chiasm.
- These tumors can cause significant visual impairment due to their proximity to critical visual pathways.
- Long-term visual outcomes after surgical treatment are not well-established.
Purpose of the Study:
- To determine the long-term visual outcomes (>10 years) in patients treated surgically for suprasellar meningiomas.
- To assess the rate and timing of tumor recurrence after surgery.
- To identify factors influencing visual prognosis and recurrence.
Main Methods:
- Retrospective case series analysis of 18 patients who underwent surgery for suprasellar meningioma.
- Review of long-term follow-up data, including visual acuity and neuroimaging.
- Correlation of visual outcomes with tumor recurrence and treatment modalities.
Main Results:
- No patient experienced postoperative worsening of vision in both eyes.
- Over 10 years, 56% maintained stable vision in both eyes; 33% lost vision in one eye; 11% lost vision in both eyes.
- Tumor recurrence or growth was observed in 39% of patients, often occurring >10 years post-surgery, even after presumed gross total resection.
- Vision worsening was associated with tumor recurrence, and subsequent treatments were often ineffective.
Conclusions:
- Long-term visual prognosis after suprasellar meningioma surgery is generally excellent.
- Tumor recurrence is a significant concern, necessitating long-term surveillance with clinical exams and neuroimaging.
- Postoperative radiation therapy is recommended for incompletely resected tumors to manage recurrence risk.